News

Thornton & Ross News

Bottle of Allens Cough Medicine

Thornton & Ross Ltd acquires the Allens brand

September 2010
Thornton & Ross Ltd is pleased to announce that it has completed the purchase of the Allens brand from Allens & Co (Anglesey) Ltd.

Established in the early 1900’s, the Allens brand has established a loyal and growing consumer base with a range which consists of Allens Pine & Honey Balsam, Allens Original Cough Lozenge, Allens Menthol & Blackcurrant Cough Lozenge and Allens Extra Strong Cough Lozenge.

The purchase includes all intellectual property, trademarks and stocks relating to these licences and the company will take over the sales, distribution and marketing of the products with immediate effect.

Dieno George, Chief Executive of Thornton & Ross said “The acquisition is in line with Thornton & Ross’ core competencies and is set to broaden our distribution base with an introduction to new trade sectors. Furthermore, the Allens range will enhance our growing presence in the cough market which is lead by Covonia, the UK’s No 2 and fastest growing major cough brand. Overall Thornton & Ross will now supply more than 1 out of every 5 bottles of cough medicine sold in the UK each year.”

The previous distributors Allens & Co (Anglesey) Ltd, will be forwarding details of all outstanding orders to Thornton & Ross for delivery and invoicing. Thornton & Ross will be communicating directly with all existing Allens Brand customers in order to ensure a smooth transition of the business.

Thornton & Ross Ltd are based in Huddersfield, West Yorkshire and produce a number of medicinal and household products, including Covonia cough medicines, the Care range, the largest volume brand sold in pharmacy, Hedrin, a breakthrough treatment for head lice, and Zoflora the leading floral disinfectant.

Further product and ordering information can be obtained from the Thornton & Ross Customer Service team on 01484-848200.

News

STADA to Become a Major Pharma Player in Ukraine by Acquiring Biopharma's Pharmaceutical Prescription and Consumer Health Business

The STADA Group continues its growth trajectory in Europe. The company, announced that it is acquiring the pharmaceutical business of Biopharma, one of the key pharmaceutical producers in Ukraine.

Click for more info

Is veganism good for your health?

The Future of Your Health report indicates that nearly a third of Brits don’t think so

Click for more info

ALVOTECH AND STADA AGREE ON STRATEGIC BIOSIMILAR PARTNERSHIP

Biopharmaceutical company Alvotech and global pharmaceutical company STADA Arzneimittel AG ("STADA") today announced that they have entered into an exclusive strategic partnership for the commercialisation of seven biosimilars in all key European markets and selected markets outside Europe.

Click for more info

STADA invests $660 Million USD in Takeda's OTC portfolio in Russia/CIS to become a major player in these branded markets

STADA to acquire a portfolio of approximately 20 selected OTC and prescription pharmaceutical products in Russia, Georgia and CIS countries

Click for more info

STADA to acquire Walmark - a leading Consumer Healthcare company in Central Europe

STADA Arzneimittel AG ('STADA' or 'the Group') today announces the acquisition of Walmark a.s. ('Walmark' or 'the company') from Mid Europa Partners for an undisclosed consideration.

Click for more info

Q&A 2019 Pharmacy Show

A Q&A Session with Phoebe Buckley on the 2019 Pharmacy Show

Click for more info

STADA Health Report 2019

More than half of people in UK are optimistic about the future of health

Click for more info

Leading pharmaceutical company invests in seven-figure state-of-the-art facility

Huddersfield pharmaceutical company Thornton & Ross is expanding, with a new seven-figure state-of-the-art facility due to open at the beginning of January.

Click for more info

>> News Archive